SCHEMBL6484290

SCHEMBL6484290

COC(=O)N1CC2CCC(Nc3cccc(F)c3C#N)CC2CC1C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 6/20 0.35
GRIA2 P42262 4/20 0.35
KCNH2 Q12809 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
TAS1R2 Q8TE23 1/20 0.32
DPP4 P27487 1/20 0.32
DPP9 Q86TI2 1/20 0.32
CYP3A4 P08684 3/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
CD274 Q9NZQ7 1/20 0.31
GPR6 P46095 1/20 0.31
CHRM3 P20309 1/20 0.31
PGR P06401 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493877 0.90 GRIK1 (0.39) GRIK1GRIA2KCNH2HRH3GPR6
SCHEMBL6493024 0.89 GRIK1 (0.38) GRIK1GRIA2DPP4DPP9CYP3A4
SCHEMBL6495295 0.85 GRIK1 (0.39) GRIK1GRIA2TAS1R3TAS1R1TAS1R2
SCHEMBL6500575 0.79 GRIK1 (0.39) GRIK1GRIA2CYP3A4MEN1KMT2A
SCHEMBL6488979 0.78 FABP5 (0.40) GRIK1GRIA2CYP3A4KMT2APGR
SCHEMBL3303727 0.75 GRIK1 (0.42) GRIK1GRIA2GPR119
SCHEMBL3394535 0.75 GRIK1 (0.42) GRIK1GRIA2GPR119
SCHEMBL6494432 0.75 GRIK1 (0.44) GRIK1GRIA2MEN1KMT2A
SCHEMBL6484834 0.72 TACR1 (0.41) DPP4CYP3A4MEN1KMT2A
SCHEMBL6488447 0.72 GRIK1 (0.37) GRIK1GRIA2KCNH2HRH3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924294-B2 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY (US) 2005-08-02 US disclosed
US-20040053961-A1 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY 2004-03-18 US disclosed
EP-1351689-A2 DERIVATIVES OF THE (3S, 4AR, 6S, 8AR) 6-PHENYLAMINO-1,2,3,4,4A,5,6,7,8,8A-DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES ELI LILLY AND COMPANY (US) 2003-10-15 EP disclosed
WO-2003024934-A2 DERIVATIVES OF THE (3S, 4AR, 6S, 8AR) 6-PHENYLAMINO-1, 2, 3, 4, 4A, 5, 6, 7, 8, 8A-DECAHYDRO ISOQUINOLINE-3-CARBOXYLIC ACID AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES ELI LILLY AND COMPANY (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053961-A1 Excitatory amino acid receptor antagonists SLC1A2, SLC1A1, SLC1A3 GRIK1 12/4885GRIA2 24/4885KCNH2 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.